Résumé
L’objectif de cette étude était de comparer les attitudes théoriques par rapport à la participation ou non à un essai randomisé contrôlé (ERC) de trois groupes comparables de patientes suivies prospectivement (cancer du sein non métastatique traité par chimiothérapie standard): ayant eu une proposition de participer à un ERC (201 acceptations, 66 refus) ou pas (n = 188). Le refus de participer semble être une décision personnelle, alors que le souhait reflète davantage l’approbation de la proposition du médecin. Lors de la proposition de participation, les médecins doivent faire face à une aversion envers le procédé de randomisation et discuter abondamment des raisons et de l’importance de la randomisation ainsi que de tous les aspects de la participation à un ERC afin de transmettre aux patients toute l’information nécessaire pour prendre une décision informée.
Abstract
The aim of this study was to compare, theoretically, attitudes towards participating or declining to participate in a hypothetical randomized controlled trial (RCT) involving three comparable breast cancer patient groups surveyed prospectively (non-metastatic cancer treated with standard chemotherapy): some patients were invited to participate in the clinical RCT (201 acceptances, 66 refusals) and others were not (n = 188). Patients’ acceptance to participate reflected their physicians’ approval, whereas refusal was usually a personal choice. When proposing RCTs, physicians must address patients’ negative preconceptions about randomization. Physicians should thoroughly discuss the reasons for and importance of randomization as well as the other aspects of participating in clinical trials in order to provide patients with all the information they need to make informed decisions.
Références
Bonneterre J, Roche H, Kerbrat P, et al. (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23: 2686–2693
Bredart A, Razavi D, Robertson C, et al. (2001) A comprehensive assessment of satisfaction with care: preliminary psychometric analysis in French, Polish, Swedish and Italian oncology patients. Patient Educ Couns 43: 243–252
Cox K, McGarry J (2003) Why patients don’t take part in cancer clinical trials: an overview of the literature. Eur J Cancer Care (Engl) 12: 114–122
Degner LF, Kristjanson LJ, Bowman D, et al. (1997) Information needs and decisional preferences in women with breast cancer. Jama 277: 1485–1492
Ellis PM (2000) Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. Ann Oncol 11: 939–945
Ellis PM, Butow PN, Tattersall MH, et al. (2001) Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol 19: 3554–3561
Ellis PM, Dowsett SM, Butow PN, et al. (1999) Attitudes to randomized clinical trials amongst outpatients attending a medical oncology clinic. Health Expect 2: 33–43
Fayter D, McDaid C, Ritchie G, et al. (2006) A systematic review of the barriers, modifiers and benefits involved in participation in cancer clinical trials. York: Centre for Reviews and Dissemination (CRD), University of York
Fleissig A, Jenkins V, Fallowfield L (2001) Results of an intervention study to improve communication about randomised clinical trials of cancer therapy. Eur J Cancer 37: 322–331
Gotay CC (2006) Increasing trial generalizability. J Clin Oncol 24: 846–847
Hann D, Winter K, Jacobsen P (1999) Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res 46: 437–443
Jenkins V, Fallowfield L (2000) Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer 82: 1783–1788
Jenkins V, Fallowfield L, Cox A (2005) The preferences of 600 patients for different descriptions of randomisation. Br J Cancer 92: 807–810
Joffe S, Weeks JC (2002) Views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst 94: 1847–1853
Julian-Reynier C, Geneve J, Dalenc F, et al. (2007) Assessment of care by breast cancer patients participating or not in a randomized controlled trial. J Clin Oncol 25: 3038–3044
Llewellyn-Thomas HA, McGreal MJ, Thiel EC (1995) Cancer patients’ decision-making and trial-entry preferences: the effects of “framing” information about short-term toxicity and long-term survival. Med Decis Making 15: 4–12
Llewellyn-Thomas HA, McGreal MJ, Thiel EC, et al. (1991) Patients’ willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. Soc Sci Med 32: 35–42
Micallef J, McGlangeaud-Freudenthal N, Aurran Y, et al. (1998) Measurement of anxiety state in women: a short-from scale. Rev Epidemiol Sante Publique 46: 383–389
Mills EJ, Seely D, Rachlis B, et al. (2006) Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 7: 141–148
Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. Jama 291: 2720–2726
Peppercorn JM, Weeks JC, Cook EF, et al. (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363: 263–270
Ross S, Grant A, Counsell C, et al. (1999) Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 52: 1143–1156
Simon MS, Du W, Flaherty L, et al. (2004) Factors associated with breast cancer clinical trials participation and enrolment at a large academic medical center. J Clin Oncol 22: 2046–2052
Stevens T, Ahmedzai SH (2004) Why do breast cancer patients decline entry into randomised trials and how do they feel about their decision later: a prospective, longitudinal, in-depth interview study. Patient Educ Couns 52: 341–348
Stryker JE, Wray RJ, Emmons KM, et al. (2006) Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns 63: 104–109
Vist GE, Hagen KB, Devereaux PJ, et al. (2005) Systematic review to determine whether participation in a trial influences outcome. BMJ 330: 1175
Wright JR, Whelan TJ, Schiff S et al. (2004) Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. J Clin Oncol 22: 4312–4318
Zubrod C, Schneiderman M, Frei EJ (1960) Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard a triethylene thiophosphoramide. J Chronic Dis 11: 7–33
Author information
Authors and Affiliations
Consortia
Corresponding author
About this article
Cite this article
Mancini, J., Genève, J., Dalenc, F. et al. Décision de participer à un essai clinique en cancérologie: influence du vécu sur les attitudes. Oncologie 10, 149–154 (2008). https://doi.org/10.1007/s10269-007-0827-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-007-0827-6